Insider at Cellebrite (CLBT) plans Rule 144 sale of 1,165 shares

Rhea-AI Filing Summary

David Gee, a shareholder of Cellebrite DI Ltd., filed a notice of proposed sale under Rule 144 to sell 1,165 ordinary shares (par value NIS 0.00001), with an aggregate market value of $16,612.90, through Morgan Stanley Smith Barney on or about February 12, 2026.

The filing notes that these securities relate to restricted share units that vested on February 12, 2026 under an issuer S-8 registered plan, with 2,618 shares acquired as employee compensation. The notice also reports prior sales in the last three months totaling 3,704 shares for $63,121.53 and 1,969 shares for $33,236.72, and states that 248,830,759 ordinary shares were outstanding. Gee represents that he is not aware of undisclosed material adverse information about Cellebrite.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, par value NIS 0.00001	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Floor New York NY 10004	1165	16612.90	248830759	02/12/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares, par value NIS 0.00001	02/12/2026	Restricted Share Units Vested Under an Issuer S-8 Registered Plan	Cellebrite DI Ltd.			2618	02/11/2026	Employee compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
David Gee 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	Ordinary shares, par value NIS 0.00001	11/21/2025	3704	63121.53
David Gee 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	Ordinary shares, par value NIS 0.00001	11/24/2025	1969	33236.72

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Cellebrite (CLBT) disclose?

The filing discloses that shareholder David Gee plans to sell 1,165 Cellebrite ordinary shares under Rule 144. The planned sale has an aggregate market value of $16,612.90 and will be executed through Morgan Stanley Smith Barney around February 12, 2026.

How many Cellebrite (CLBT) shares is David Gee planning to sell?

David Gee plans to sell 1,165 ordinary shares of Cellebrite DI Ltd. The filing lists these shares with an aggregate market value of $16,612.90, to be sold on or about February 12, 2026 through Morgan Stanley Smith Barney on the Nasdaq exchange.

How were the Cellebrite (CLBT) shares in the Form 144 acquired?

The shares relate to restricted share units that vested on February 12, 2026 under a Cellebrite S-8 registered equity plan. The filing states that 2,618 ordinary shares were acquired from Cellebrite DI Ltd. as employee compensation, with payment dated February 11, 2026.

What prior Cellebrite (CLBT) share sales has David Gee reported in the last 3 months?

The notice reports two recent sales by David Gee. On November 21, 2025, he sold 3,704 ordinary shares for $63,121.53. On November 24, 2025, he sold 1,969 ordinary shares for $33,236.72. Both transactions involved Cellebrite ordinary shares with par value NIS 0.00001.

How many Cellebrite (CLBT) shares are outstanding according to this filing?

The Form 144 lists 248,830,759 ordinary shares of Cellebrite DI Ltd. as outstanding. This figure provides context for the relative size of the planned 1,165-share sale disclosed in the notice compared to the company’s total ordinary shares.

What representation does the seller make about Cellebrite (CLBT) information in this Form 144?

The seller represents that he does not know any material adverse information about Cellebrite’s current or prospective operations that has not been publicly disclosed. This statement is required when filing a notice of proposed sale of securities under Rule 144.